Ocugen’s CFO Bets on Her Own Stock as a Packed Conference Schedule Previews a Pivotal Summer

The clinical calendar is tightening for Ocugen, and the stock is starting to stir in anticipation. Shares closed the week at €1.12, up 2.2 percent on the day and 6.7 percent over the past five sessions — a modest but notable recovery after slipping more than 50 percent from this year’s March peak of €2.35. A surge in trading volume on Friday, with roughly 26.3 million shares changing hands compared with a daily average of 7.4 million, suggests investors are positioning ahead of a dense run of catalysts.

One early signal of conviction has come from the executive suite. On June 15, Chief Financial Officer Treerita Essalima Johnson-Greene bought 21,000 shares on the open market for around $25,800, lifting her stake by about 4.2 percent to 521,000 shares. That single purchase stands alone inside the past six months as the only insider transaction on the open book — and it was a buy, not a sale.

The immediate focus now shifts to San Diego. Ocugen is scheduled to present its modifier gene therapy platform on Tuesday, June 23, at 11:00 a.m. PDT in Theater 3 of the BIO International Convention, which runs from June 22 to 25 at the San Diego Convention Center. The appearance rounds out a busy month on the conference circuit that already included stops at the Noble Capital Markets Emerging Growth Virtual Equity Conference and the Clinical Trials at the Summit 2026.

Yet the main event lies in the third quarter, when three clinical milestones converge within a single window. Ocugen expects to release interim data from the Phase 2/3 GARDian3 trial of OCU410ST, a gene therapy candidate for Stargardt disease. The study enrolled 63 patients, and the interim analysis will be triggered once 24 of them have completed the eight-month follow-up.

The bar has been set by earlier results. In the predecessor GARDian study, treated eyes showed a 48 percent slower rate of lesion growth over 12 months along with a gain of nearly nine letters in best-corrected visual acuity — a statistically significant and clinically meaningful improvement.

Should investors sell immediately? Or is it worth buying Ocugen?

At the same time, Ocugen is laying the groundwork for a Biologics License Application for OCU400 and launching Phase 3 for OCU410. Together, the programs target three BLAs by 2028. The company plans to file for OCU400 and OCU410ST before the end of 2027, with topline GARDian3 data expected in the second quarter of next year.

Management has taken steps to fortify the balance sheet ahead of this testing period. In May, Ocugen raised $130 million through private placements of convertible notes paying 6.75 percent interest and maturing in 2034. Roughly $32.7 million of that has gone to repay an outstanding loan from Avenue Capital Group. The remaining cash is expected to sustain operations into 2028.

The recent annual general meeting on June 11 added further stability. Shareholders elected Kirsten Castillo and Satish Chandran to the board with terms through 2029, while Mohamed Genead was confirmed as permanent Chief Medical Officer after serving on an interim basis since May 8.

As the stock hovers at €1.12 — about 12 percent below its 50-day moving average of €1.27 and roughly 15 percent below the 200-day average — the technical picture remains strained. The relative strength index of 46.4 sits in neutral territory, leaving room for a move in either direction. With four analysts assigning a “Strong Buy” rating, the coming weeks will test whether the pipeline can close the gap to the March high.